News coverage about Charles River Laboratories Intl. (NYSE:CRL) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Charles River Laboratories Intl. earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.692498074419 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

CRL has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price target on the stock in a research report on Friday, May 11th. TheStreet upgraded shares of Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research report on Thursday, May 10th. KeyCorp upgraded shares of Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and lifted their price target for the stock from $115.85 to $130.00 in a research report on Friday, June 15th. Bank of America lifted their price target on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, July 16th. Finally, Royal Bank of Canada upgraded shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price target on the stock in a research report on Tuesday, July 17th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $125.40.

Charles River Laboratories Intl. stock opened at $124.71 on Wednesday. Charles River Laboratories Intl. has a 52 week low of $96.70 and a 52 week high of $130.66. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. The company has a market capitalization of $5.93 billion, a P/E ratio of 23.66, a PEG ratio of 1.55 and a beta of 0.66.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The firm had revenue of $585.30 million during the quarter, compared to analyst estimates of $570.65 million. During the same quarter last year, the business posted $1.29 EPS. The company’s revenue was up 24.8% on a year-over-year basis. equities analysts forecast that Charles River Laboratories Intl. will post 5.91 EPS for the current year.

In related news, insider Birgit Girshick sold 3,978 shares of the firm’s stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $119.90, for a total value of $476,962.20. Following the completion of the transaction, the insider now owns 18,999 shares of the company’s stock, valued at approximately $2,277,980.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Davide Molho sold 11,600 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $125.00, for a total transaction of $1,450,000.00. Following the completion of the transaction, the chief operating officer now directly owns 22,079 shares of the company’s stock, valued at approximately $2,759,875. The disclosure for this sale can be found here. Insiders sold a total of 33,258 shares of company stock valued at $4,001,244 in the last ninety days. Company insiders own 2.10% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Short Selling Stocks, A Beginner’s Guide

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.